Ποια είναι η τιμή για EFFECTOR Therapeutics, Inc. (EFTRW)

Η τιμή για EFFECTOR Therapeutics, Inc. (EFTRW) είναι $0.0006

Ποια είναι η κεφαλαιοποίηση αγοράς για EFFECTOR Therapeutics, Inc. (EFTRW)

Η κεφαλαιοποίηση αγοράς για EFFECTOR Therapeutics, Inc. (EFTRW) είναι $2.82K

EFFECTOR Therapeutics, Inc. (EFTRW) Ιστορικό Τιμών

eFFECTOR Therapeutics, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective translation regulator inhibitors aimed at combating cancer. Their primary investigational drug, Tomivosertib, is an orally administered small-molecule MNK inhibitor currently undergoing Phase 2b clinical trials. This candidate is being evaluated for its efficacy in patients suffering from metastatic non-small cell lung cancer. Additionally, the company is advancing zotatifin, another small molecule engineered to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 1/2 clinical studies for individuals with various solid tumors. Furthermore, it's being tested in a Phase 2a open-label expansion cohort, in conjunction with fulvestrant and abemaciclib, for patients afflicted with ER-positive breast cancer. eFFECTOR Therapeutics, Inc. also holds a research collaboration and licensing pact with Pfizer Inc., focused on co-developing eIF4E inhibitors. Established in 2012, the company maintains its corporate headquarters in Solana Beach, California.

Έτος	Απόδοση
2026 (TTM)	0.00%
2025	59,900.00%
2024	-100.00%
2023	12.00%
2022	-85.79%
2021	0.00%

Έτος

Απόδοση

2026 (TTM)

0.00%

2025

59,900.00%

2024

-100.00%

2023

12.00%

2022

-85.79%

2021

0.00%

Εταιρεία	Τιμή μετοχής	Μεταβολή 1Έτ%	Χώρα
Vertex Pharmaceuticals Incorporated VRTX.US	$527.87	36.13%	US
Argenx SE ARGX.US	$873.57	37.02%	NL
Lonza Group AG LONN.SW	$736.38	8.73%	CH
UCB S.A. UCB.BR	$263.09	20.45%	BE
Samsung Biologics Co.,Ltd. 207940.KS	$1.07K	-5.56%	KR

Εταιρεία

Τιμή μετοχής

Μεταβολή 1Έτ%

Χώρα